Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Delayed Quote. Delayed  - 07/22 03:53:02 pm
70 EUR   +1.29%
07/05 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize l..
07/04 UCB : and Daiichi Sankyo announce Japanese approval of lacosamide (b..
06/10 UCB : bimekizumab demonstrates positive results in early development..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
07/18/2016 07/19/2016 07/20/2016 07/21/2016 07/22/2016 Date
67.876(c) 68.195(c) 68.955(c) 69.11(c) 70(c) Last
0 0 10 0 200 Volume
+0.37% +0.47% +1.11% +0.22% +1.29% Change
More quotes
Financials (€)
Sales 2016 4 042 M
EBIT 2016 729 M
Net income 2016 449 M
Debt 2016 955 M
Yield 2016 1,80%
Sales 2017 4 290 M
EBIT 2017 887 M
Net income 2017 544 M
Debt 2017 606 M
Yield 2017 1,91%
P/E ratio 2016 28,19
P/E ratio 2017 22,83
EV / Sales2016 3,63x
EV / Sales2017 3,33x
Capitalization 13 701 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra, and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
07/05 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize lacosamide in..
07/04 UCB : and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VI..
06/10 UCB : bimekizumab demonstrates positive results in early development in patients..
06/08 UCB : commitment to addressing real world patient needs on display at the Annual..
05/31 UCB : BRIVIACT® now available in U.S. pharmacies for epilepsy patients living wi..
05/19 UCB : Patent Issued for Systems for Automatically Administering Medication (USPT..
05/02 UCB FIRST THREE MONTHS INTERIM REPOR :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : Patent Issued for Method for Producing Protein (USPTO 9315565)
04/28 UCB : shareholder meeting today
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 78,7 €
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA-17.78%15 037
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
More Results